<p>隨着澳大利亞市場在商品價格穩定和華爾街強勁表現的推動下，預計本週將以積極的態勢收尾，投資者正在關注各個領域的機會。儘管 “便士股票” 這一名稱有些過時，但對於那些尋求小型或新興公司潛在價值和增長的投資者來説，仍然是一個引人注目的領域。這些股票在穩健的財務基礎上，結合資產負債表的強勁表現，能夠提供可觀的回報。</p>
<h3>澳大利亞十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 便士股票篩選器中的 441 只股票的完整列表。</p>
<p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
<h2>BKI Investment (ASX:BKI)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BKI Investment Company Limited 是一家公開上市的投資管理公司，市值為 14.6 億澳元。</p>
<p><strong>運營：</strong> BKI Investment 的收入完全來自證券行業，金額為 6933 萬澳元。</p>
<p><strong>市值：</strong> A$1.46B</p>
<p>BKI Investment Company Limited 市值為 14.6 億澳元，憑藉無債務狀態和高質量收益展現出財務穩定性。儘管來自證券行業的收入穩定為 6933 萬澳元，但公司最近的財報顯示淨收入較去年略有下降，降至 6186 萬澳元。儘管股息收益率仍具吸引力，達到 4.35%，但未能完全由收益或自由現金流覆蓋，這引發了可持續性擔憂。最近的董事會變動包括亞歷山大·佩恩先生新被認定為獨立董事，可能增強 BKI 成熟董事會結構內的治理動態。</p>
<ul>
<li>在這裏深入瞭解 BKI Investment 的具體情況，查看我們的詳細資產負債表健康報告。</li>
<li>通過我們的詳細歷史業績報告評估 BKI Investment 的過去業績。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis"/></p>
<p>截至 2025 年 9 月的 ASX:BKI 財務狀況分析</p>
<h2>Dimerix (ASX:DXB)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Dimerix Limited 是一家生物製藥公司，專注於開發和商業化滿足澳大利亞未滿足醫療需求的藥品，市值為 2.8809 億澳元。</p>
<p><strong>運營：</strong> 公司的收入完全來自職業藥物檢測設備和新治療劑的開發，金額為 559 萬澳元。</p>
<p><strong>市值：</strong> A$288.09M</p>
<p>Dimerix Limited 市值為 2.8809 億澳元，儘管報告了截至 2025 年 6 月 30 日的銷售額為 559 萬澳元，但仍處於無收入狀態。公司處於虧損狀態，淨虧損為 1325 萬澳元，但由於自由現金流為正，其現金流持續超過三年。Dimerix 的管理層和董事會經驗豐富，平均任期分別為 4.3 年和 7.9 年，這可能有助於在行業挑戰中提供戰略方向。該股票的交易價格顯著低於估計的公允價值，並且無債務，短期資產大幅超過負債。</p>
<ul>
<li>在這裏深入瞭解 Dimerix 的完整分析健康報告。</li>
<li>通過查看我們的業績歷史報告瞭解 Dimerix 的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月的 ASX:DXB 收入與支出明細</p>
<h2>Kingsgate Consolidated (ASX:KCN)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Kingsgate Consolidated Limited 從事黃金和白銀礦產的勘探、開發和開採，市值為 7.6712 億澳元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其 Chatree 部門，產生了 3.3675 億澳元的收入。</p>
<p><strong>市值：</strong> A$767.12M</p>
<p>Kingsgate Consolidated Limited 市值為 7.6712 億澳元，報告了來自其 Chatree 部門的顯著收入增長，達到截至 2025 年 6 月 30 日的 3.3675 億澳元。然而，淨收入從去年的 1.9976 億澳元下降至 2946 萬澳元，原因是利潤率和每股收益下降。公司在五年內成功降低了其債務與股本比率，並保持相對滿意的淨債務水平。儘管每週波動穩定且過去收益質量高，但當前的利息覆蓋率仍低於最佳水平，表明在有效管理財務義務方面可能面臨挑戰。</p>
<ul>
<li>在我們的財務健康報告中更仔細地瞭解 Kingsgate Consolidated 的潛力。</li>
<li>通過訪問我們的收益增長報告評估 Kingsgate Consolidated 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月的 ASX:KCN 債務與股本歷史及分析</p>
<h2>關鍵要點</h2>
<ul>
<li>點擊這裏訪問我們完整的 441 只 ASX 便士股票指數。</li>
<li>對其他可能性感興趣？我們發現 17 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

<p>BKI 投資和另外兩隻 ASX 便士股票被認為是在積極的市場前景下的潛在投資機會。BKI 投資公司（BKI Investment Company Limited）市值為 14.6 億澳元，顯示出財務穩定性，但對其股息可持續性存在擔憂。Dimerix Limited 是一家生物製藥公司，尚未產生收入，但擁有穩定的現金流。Kingsgate Consolidated Limited 專注於黃金和白銀開採，報告了收入增長，但淨收入下降。投資者被鼓勵探索這些股票以尋找潛在的價值和增長</p>

<p>As the Australian market looks to end the week on a positive note, buoyed by steady commodities and a strong overnight performance on Wall Street, investors are eyeing opportunities in various segments. Penny stocks, despite their somewhat outdated name, remain an intriguing area for those seeking potential value and growth in smaller or newer companies. With solid financial foundations, these stocks can offer promising returns as they combine balance sheet strength with potential for significant gains.</p>
<div class="lb-trans"><p>隨着澳大利亞市場在商品價格穩定和華爾街強勁表現的推動下，預計本週將以積極的態勢收尾，投資者正在關注各個領域的機會。儘管 “便士股票” 這一名稱有些過時，但對於那些尋求小型或新興公司潛在價值和增長的投資者來説，仍然是一個引人注目的領域。這些股票在穩健的財務基礎上，結合資產負債表的強勁表現，能夠提供可觀的回報。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>回報與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.47</td>
<td>A$134.7M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.19</td>
<td>A$103.31M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.85</td>
<td>A$52.93M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.80</td>
<td>A$432.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.73</td>
<td>A$275.3M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.0745</td>
<td>A$38.57M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.34</td>
<td>A$357.38M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tasmea (ASX:TEA)</td>
<td>A$4.43</td>
<td>A$1.08B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.79</td>
<td>A$377.78M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 441 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 便士股票篩選器中的 441 只股票的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>讓我們更仔細地看看我們從篩選公司中挑選的幾隻股票。</p>
</div><h2>BKI Investment (ASX:BKI)</h2>
<div class="lb-trans"><h2>BKI Investment (ASX:BKI)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BKI Investment Company Limited is a publicly owned investment manager with a market cap of A$1.46 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> BKI Investment Company Limited 是一家公開上市的投資管理公司，市值為 14.6 億澳元。</p>
</div><p><strong>Operations:</strong> BKI Investment's revenue is derived entirely from the Securities Industry, amounting to A$69.33 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> BKI Investment 的收入完全來自證券行業，金額為 6933 萬澳元。</p>
</div><p><strong>Market Cap:</strong> A$1.46B</p>
<div class="lb-trans"><p><strong>市值：</strong> A$1.46B</p>
</div><p>BKI Investment Company Limited, with a market cap of A$1.46 billion, demonstrates financial stability through its debt-free status and high-quality earnings. Despite a steady revenue stream of A$69.33 million from the securities industry, the company's recent earnings report shows a slight decline in net income to A$61.86 million from last year. The dividend yield remains attractive at 4.35%, although it is not fully covered by earnings or free cash flows, raising sustainability concerns. Recent board changes include Mr. Alexander Payne's newly recognized independence as a director, potentially enhancing governance dynamics within BKI's seasoned board structure.</p>
<div class="lb-trans"><p>BKI Investment Company Limited 市值為 14.6 億澳元，憑藉無債務狀態和高質量收益展現出財務穩定性。儘管來自證券行業的收入穩定為 6933 萬澳元，但公司最近的財報顯示淨收入較去年略有下降，降至 6186 萬澳元。儘管股息收益率仍具吸引力，達到 4.35%，但未能完全由收益或自由現金流覆蓋，這引發了可持續性擔憂。最近的董事會變動包括亞歷山大·佩恩先生新被認定為獨立董事，可能增強 BKI 成熟董事會結構內的治理動態。</p>
</div><ul>
<li>Dive into the specifics of BKI Investment here with our thorough balance sheet health report.</li>
<li>Assess BKI Investment's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 BKI Investment 的具體情況，查看我們的詳細資產負債表健康報告。</li>
<li>通過我們的詳細歷史業績報告評估 BKI Investment 的過去業績。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/ce30ff96-4907-433a-8e72-16c855a12dcf/chart/financial-position-analysis"/></p>
<p>ASX:BKI Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:BKI 財務狀況分析</p>
</div><h2>Dimerix (ASX:DXB)</h2>
<div class="lb-trans"><h2>Dimerix (ASX:DXB)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Dimerix Limited is a biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs in Australia, with a market cap of A$288.09 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dimerix Limited 是一家生物製藥公司，專注於開發和商業化滿足澳大利亞未滿足醫療需求的藥品，市值為 2.8809 億澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived entirely from the development of occupational drug testing devices and new therapeutic agents, amounting to A$5.59 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入完全來自職業藥物檢測設備和新治療劑的開發，金額為 559 萬澳元。</p>
</div><p><strong>Market Cap:</strong> A$288.09M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$288.09M</p>
</div><p>Dimerix Limited, with a market cap of A$288.09 million, remains pre-revenue despite reporting sales of A$5.59 million for the year ended June 30, 2025. The company is unprofitable with a net loss of A$13.25 million, though its cash runway is secure for over three years due to positive free cash flow. Dimerix's management and board are experienced, averaging tenures of 4.3 and 7.9 years respectively, which may aid strategic direction amidst industry challenges. The stock trades significantly below estimated fair value and remains debt-free with short-term assets exceeding liabilities by a substantial margin.</p>
<div class="lb-trans"><p>Dimerix Limited 市值為 2.8809 億澳元，儘管報告了截至 2025 年 6 月 30 日的銷售額為 559 萬澳元，但仍處於無收入狀態。公司處於虧損狀態，淨虧損為 1325 萬澳元，但由於自由現金流為正，其現金流持續超過三年。Dimerix 的管理層和董事會經驗豐富，平均任期分別為 4.3 年和 7.9 年，這可能有助於在行業挑戰中提供戰略方向。該股票的交易價格顯著低於估計的公允價值，並且無債務，短期資產大幅超過負債。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Dimerix.</li>
<li>Understand Dimerix's track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 Dimerix 的完整分析健康報告。</li>
<li>通過查看我們的業績歷史報告瞭解 Dimerix 的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/2af6f193-a47c-4ab6-a34a-c1f1aabe8db6/chart/revenue-and-expenses-breakdown"/></p>
<p>ASX:DXB Revenue &amp; Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:DXB 收入與支出明細</p>
</div><h2>Kingsgate Consolidated (ASX:KCN)</h2>
<div class="lb-trans"><h2>Kingsgate Consolidated (ASX:KCN)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties, with a market cap of A$767.12 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kingsgate Consolidated Limited 從事黃金和白銀礦產的勘探、開發和開採，市值為 7.6712 億澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Chatree segment, which generated A$336.75 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其 Chatree 部門，產生了 3.3675 億澳元的收入。</p>
</div><p><strong>Market Cap:</strong> A$767.12M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$767.12M</p>
</div><p>Kingsgate Consolidated Limited, with a market cap of A$767.12 million, reported significant revenue growth from its Chatree segment, reaching A$336.75 million for the year ended June 30, 2025. However, net income declined to A$29.46 million from the previous year's A$199.76 million due to reduced profit margins and earnings per share. The company has successfully reduced its debt-to-equity ratio over five years and maintains satisfactory net debt levels relative to equity. Despite stable weekly volatility and high-quality past earnings, current interest coverage remains below optimal levels, indicating potential challenges in managing financial obligations effectively.</p>
<div class="lb-trans"><p>Kingsgate Consolidated Limited 市值為 7.6712 億澳元，報告了來自其 Chatree 部門的顯著收入增長，達到截至 2025 年 6 月 30 日的 3.3675 億澳元。然而，淨收入從去年的 1.9976 億澳元下降至 2946 萬澳元，原因是利潤率和每股收益下降。公司在五年內成功降低了其債務與股本比率，並保持相對滿意的淨債務水平。儘管每週波動穩定且過去收益質量高，但當前的利息覆蓋率仍低於最佳水平，表明在有效管理財務義務方面可能面臨挑戰。</p>
</div><ul>
<li>Take a closer look at Kingsgate Consolidated's potential here in our financial health report.</li>
<li>Evaluate Kingsgate Consolidated's prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更仔細地瞭解 Kingsgate Consolidated 的潛力。</li>
<li>通過訪問我們的收益增長報告評估 Kingsgate Consolidated 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6ebaac19-4401-459e-b09a-25df53b825b0/chart/debt-equity-history-analysis"/></p>
<p>ASX:KCN Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 ASX:KCN 債務與股本歷史及分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Click here to access our complete index of 441 ASX Penny Stocks.</li>
<li>Interested In Other Possibilities? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 441 只 ASX 便士股票指數。</li>
<li>對其他可能性感興趣？我們發現 17 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

BKI 投資及其他兩個 ASX 低價股值得考慮